The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …

A novel series of alkoxyimino derivatives as S1P 1 agonists were discovered through de
novo design using FTY720 as the chemical starting point. Extensive structure–activity …

Objective: To report outcomes of pregnancies that occurred during the fingolimod clinical
development program. Methods: Pregnancy outcomes from phase II, phase III, and phase IV …

FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new
sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis and prevention of …

Animal models are important for the investigation of human heart pathology, novel treatments,
and medical or surgical interventions for disease. Serum markers of myocardial damage …

The use of minipigs in preclinical safety testing of pharmaceuticals is considered an alternative
to the more traditional dog and nonhuman primate (NHP) nonrodent species. Substantial …

The pig was introduced more than 20 years ago in drug development following attempts of
finding a species that shares better homology with human than the dog, based on …

Blood samples were taken from the retrobulbar venous plexus or the sublingual vein of
male HanIbm:Wist rats to compare clinical pathology parameters between the two sampling …

The pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
hydrochloride (FTY720), a novel immunosuppressive agent, were examined in …

Minipigs have been used for dermal drug development studies for decades, and they are
currently more frequently considered as the second nonrodent species for pivotal nonclinical …